MBX Stock Overview
A life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Microbix Biosystems Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.35 |
| 52 Week High | CA$0.45 |
| 52 Week Low | CA$0.23 |
| Beta | 0.36 |
| 11 Month Change | 7.58% |
| 3 Month Change | 9.23% |
| 1 Year Change | 10.94% |
| 33 Year Change | -44.53% |
| 5 Year Change | 57.78% |
| Change since IPO | -40.83% |
Recent News & Updates
Recent updates
Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution
Aug 22
Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem
Feb 21Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up
Dec 23Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?
Nov 03Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?
Jul 22Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio
May 17Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook
Dec 27Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet
Aug 08Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals
May 20Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly
Feb 06One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates
Dec 28Is Microbix Biosystems (TSE:MBX) A Risky Investment?
Oct 14Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 15A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)
May 17Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable
Mar 24We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt
Jan 29
Shareholder Returns
| MBX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 2.9% | 2.1% | 1.4% |
| 1Y | 10.9% | -40.0% | 14.7% |
Return vs Industry: MBX exceeded the Canadian Biotechs industry which returned -39.9% over the past year.
Return vs Market: MBX underperformed the Canadian Market which returned 15.2% over the past year.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 12.7% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MBX has not had significant price volatility in the past 3 months.
Volatility Over Time: MBX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Cameron Groome | www.microbix.com |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Microbix Biosystems Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | CA$49.12m |
| Earnings (TTM) | CA$5.08m |
| Revenue (TTM) | CA$23.36m |
9.5x
P/E Ratio2.1x
P/S RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | CA$23.36m |
| Cost of Revenue | CA$10.00m |
| Gross Profit | CA$13.37m |
| Other Expenses | CA$8.29m |
| Earnings | CA$5.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 57.21% |
| Net Profit Margin | 21.73% |
| Debt/Equity Ratio | 20.0% |
How did MBX perform over the long term?
See historical performance and comparison